JP2023540614A5 - - Google Patents
Info
- Publication number
- JP2023540614A5 JP2023540614A5 JP2023515815A JP2023515815A JP2023540614A5 JP 2023540614 A5 JP2023540614 A5 JP 2023540614A5 JP 2023515815 A JP2023515815 A JP 2023515815A JP 2023515815 A JP2023515815 A JP 2023515815A JP 2023540614 A5 JP2023540614 A5 JP 2023540614A5
- Authority
- JP
- Japan
- Prior art keywords
- cbdv
- pharmaceutical composition
- composition according
- seizures
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2014250.1A GB202014250D0 (en) | 2020-09-10 | 2020-09-10 | Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2014250.1 | 2020-09-10 | ||
| PCT/EP2021/074661 WO2022053486A1 (en) | 2020-09-10 | 2021-09-08 | Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540614A JP2023540614A (ja) | 2023-09-25 |
| JP2023540614A5 true JP2023540614A5 (enExample) | 2024-08-22 |
| JP7817990B2 JP7817990B2 (ja) | 2026-02-19 |
Family
ID=73149611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515815A Active JP7817990B2 (ja) | 2020-09-10 | 2021-09-08 | 遺伝子異常に関係する稀なてんかん症候群に関連する発作の治療におけるカンナビジバリンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346809A1 (enExample) |
| EP (1) | EP4210685B1 (enExample) |
| JP (1) | JP7817990B2 (enExample) |
| KR (1) | KR20230066417A (enExample) |
| CN (1) | CN116234580A (enExample) |
| AU (1) | AU2021341452A1 (enExample) |
| CA (1) | CA3191266A1 (enExample) |
| GB (2) | GB202014250D0 (enExample) |
| MX (1) | MX2023002837A (enExample) |
| WO (1) | WO2022053486A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| CA3264785A1 (en) | 2022-08-12 | 2024-02-15 | Jazz Pharmaceuticals Research Uk Limited | ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487183B (en) * | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2495118B (en) * | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2549278B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2569961B (en) * | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2588458A (en) * | 2019-10-25 | 2021-04-28 | Gw Res Ltd | Cannabidivarin preparations |
-
2020
- 2020-09-10 GB GBGB2014250.1A patent/GB202014250D0/en not_active Ceased
-
2021
- 2021-09-01 GB GB2112440.9A patent/GB2599492A/en not_active Withdrawn
- 2021-09-08 CN CN202180062304.9A patent/CN116234580A/zh active Pending
- 2021-09-08 WO PCT/EP2021/074661 patent/WO2022053486A1/en not_active Ceased
- 2021-09-08 US US18/044,941 patent/US20230346809A1/en active Pending
- 2021-09-08 CA CA3191266A patent/CA3191266A1/en active Pending
- 2021-09-08 MX MX2023002837A patent/MX2023002837A/es unknown
- 2021-09-08 KR KR1020237012089A patent/KR20230066417A/ko active Pending
- 2021-09-08 EP EP21769152.6A patent/EP4210685B1/en active Active
- 2021-09-08 JP JP2023515815A patent/JP7817990B2/ja active Active
- 2021-09-08 AU AU2021341452A patent/AU2021341452A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020201457B2 (en) | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | |
| MX2023012352A (es) | Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut. | |
| ES2746973T3 (es) | Extractos vegetales que contienen cannabinoides como agentes neuroprotectores | |
| CA2794620C (en) | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy | |
| HRP20140398T1 (hr) | Korištenje jednog ili neke kombinacije fitokanabinoida u lijeäśenju epilepsije | |
| IL276217B1 (en) | Using cannabinoids in the treatment of epilepsy | |
| US20140221469A1 (en) | Phytocannabinoids for use in the treatment of cancer | |
| CO2020009747A2 (es) | Métodos para purificar cannabinoides usando cromatografía líquido-líquido | |
| Cascio et al. | Known pharmacological actions of nine nonpsychotropic phytocannabinoids | |
| Rosdianto et al. | Bioactive compounds of Boesenbergia sp. and their anti-inflammatory mechanism: A review | |
| EA029697B1 (ru) | Фармацевтическая композиция, содержащая фитоканнабиноиды каннабидиварин (cbdv) и каннабидиол (cbd) | |
| FI3920891T3 (fi) | Nopeasti hajoavat kannabinoiditabletit | |
| Hiremathad | A review: Natural compounds as anti-Alzheimer's disease agents | |
| Fathilah et al. | Labisia pumila prevents complications of osteoporosis by increasing bone strength in a rat model of postmenopausal osteoporosis | |
| US20090191293A1 (en) | Composition for enhancing immunity and reducing inflammation related to infections | |
| Agarwal et al. | In Vivo Efficacy, Mechanistic Study and Synergistic Interaction of Precocene II with Norfloxacin against Methicillin‐Resistant Staphylococcus aureus | |
| ITMI20121298A1 (it) | Composizioni per la somministrazione orale aventi un effetto benefico nelle tendinopatie e nelle lesioni dei legamenti | |
| Dursun et al. | Aqueous parsley (Petroselinum crispum) extract ameliorated methotrexate-induced brain and small intestine damage in rats | |
| US20210393578A1 (en) | Brain health formulation | |
| BRPI0401592A (pt) | Extrato diclorometânico de "bidens alba l." com atividades anti-ulcerogênicas dos sesquiterpenos e poliacetilenos | |
| CL2021001076A1 (es) | Composición farmacéutica que comprende una combinación de 1,3-2,5% de tetrahidrocannabinol (thc) y 0,6-1,4% de cannabidiol (cbd); su proceso de elaboración; y su uso para el tratamiento del dolor crónico refractario. | |
| NZ764569B2 (en) | Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome | |
| NZ730985B2 (en) | Use of cannabinoids in the treatment of degenerative skeletal muscle diseases | |
| Kubow et al. | The Emergence of Polyphenols in the Potentiation of Treatment Modality in Cystic Fibrosis | |
| NZ754352A (en) | Use of cannabidiol in the treatment of angelman syndrome |